Trial · NCT01347580
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Thrombolysis In Myocardial Infarction (TIMI) Flow Grade 3 of MI Culprit Vessel at Initial Angiography (Co-primary Endpoint) | At initial angiography, pre PCI | (TIMI) flow grade classification is used to assess coronary blood flow in acute coronary syndromes. grade 0:no reperfusion, grade 1: penetration without perfusion, grade 2: Partial reperfusion, grade 3: complete perfusion. |
| Primary | ST-segment Elevation Resolution Pre PCI ≥70% (Co-primary Endpoint) | Between baseline and PCI | ST segment elevation resolution is the mean ST elevation pre-hospital minus the mean STelevation pre-PCI divided by the mean ST elevation pre-hospital. It is expressed as a percentage and split in 2 categories , complete (≥70%) versus incomplete (\<70%) resolution. |
| Secondary | 1st Composite Clinical Endpoint | during the 30 days of treatment | death/MI/stroke/urgent revascularization/stent thrombosis. Adjudicated events except death |
| Secondary | 2nd Composite Clinical Endpoint | within 30 days of study | Death/MI/urgent revascularization. Adjudicated events except death |
| Secondary | Definite Stent Thrombosis | during 30 days of treatment | Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation. It is an adjudicated endpoint |
| Secondary | TIMI Flow Grade 3 Post -PCI | at coroangiography post-PCI | TIMI) flow grade 3 is complete perfusion post-PCI. |
| Secondary | ST Segment Elevation Resolution Post-PCI >= 70% | Between baseline and ECG 60 mn post-PCI | ST segment elevation resolution post PCI \>=70% is defined as complete resolution |
| Secondary | Thrombotic Bail-out With GPIIb/IIIa Inhibitors at Initial PCI | during PCI | Glycoprotein (GP) IIb/IIIa inhibitors are often used as a rescue or bailout therapy to manage complications arising during percutaneous coronary intervention. |
| Secondary | Major Bleeds Within 48 Hours | within 48 hours of first dose | non CABG related bleeds, (PLATO definition) include Life threatening and other major bleeds |
| Secondary | Minor and Major Bleedings Within 48 Hours | within 48 hours of first dose | non CABG related bleeds (PLATO definition) |
| Secondary | Major Bleeds After 48 Hours | after 48hours post-first dose | non CABG related bleeds (PLATO definition) include life threatening and other major bleedings |
| Secondary | Minor and Major Bleeds After 48 Hours | after 48 hours post first dose | non CABG related bleeds (PLATO definition) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01347580/registered